We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and be tter improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie
NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.
Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.
Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.
Earlier use of liso-cel may improve responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.
Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase…
An abstract is unavailable.
Over the last 10 years, numerous studies have profiled human tumors by single-cell RNA-seq. In this perspective, Tirosh and Suva describe the cell states most…
This cross-sectional study estimates the prevalence of financial hardship among cancer survivors and investigates its associations with individual- and community-level characteristics.
